Hsbc Holdings PLC Sells 9,335 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Hsbc Holdings PLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 357,022 shares of the medical equipment provider’s stock after selling 9,335 shares during the period. Hsbc Holdings PLC owned 0.18% of Zimmer Biomet worth $32,151,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ZBH. Main Management ETF Advisors LLC lifted its position in shares of Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock worth $986,000 after purchasing an additional 112 shares during the last quarter. Boltwood Capital Management boosted its stake in Zimmer Biomet by 3.9% during the 4th quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after purchasing an additional 144 shares during the period. Independence Bank of Kentucky grew its holdings in Zimmer Biomet by 9.7% in the 4th quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock valued at $147,000 after buying an additional 145 shares during the last quarter. LOM Asset Management Ltd increased its position in Zimmer Biomet by 21.5% in the 4th quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 147 shares during the period. Finally, Mesirow Financial Investment Management Inc. increased its position in Zimmer Biomet by 5.9% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 2,723 shares of the medical equipment provider’s stock worth $268,000 after buying an additional 151 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Up 0.6%

Shares of Zimmer Biomet stock opened at $87.64 on Wednesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The firm has a market capitalization of $16.95 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. The company’s fifty day moving average price is $87.02 and its two-hundred day moving average price is $90.01.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the firm earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZBH shares. Truist Financial reiterated a “hold” rating and set a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 target price for the company. Stifel Nicolaus reduced their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Finally, Citizens Jmp decreased their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.